NCT07114497

Brief Summary

Aim of the Study: The aim of this study is to determine the expression levels of candidate microRNAs (miRNAs) expressed in human degenerated intervertebral disc tissues. In line with this objective, our specific goals are outlined below: Objectives: Objective 1: To include patients diagnosed with lumbar disc herniation (LDH) who are scheduled for lumbar microdiscectomy (LMD), and patients diagnosed with vertebral fractures who are scheduled for decompression or fusion surgeries, by obtaining informed consent in accordance with ethical standards. Objective 2: To collect degenerated intervertebral disc tissues obtained during LMD or spinal cord repair surgeries into cryotubes in duplicates for real-time PCR (rt-PCR) analysis, and to store them under appropriate conditions until analysis. Objective 3: To identify candidate miRNAs that regulate genes associated with the pathophysiology of intervertebral disc degeneration (IVDD) using databases such as miRBase, miRTar, and miRDB. Objective 4: To determine the expression levels of candidate miRNAs associated with nucleus pulposus cell proliferation in human degenerated disc tissues. Objective 5: To determine the expression levels of candidate miRNAs associated with apoptosis of nucleus pulposus cells in human degenerated disc tissues. Objective 6: To determine the expression levels of candidate miRNAs associated with extracellular matrix (ECM) remodeling in human degenerated disc tissues. Objective 7: To determine the expression levels of candidate miRNAs associated with cartilaginous endplate dysfunction in human degenerated disc tissues. Objective 8: To determine the expression levels of candidate miRNAs associated with annulus fibrosus degeneration in human degenerated disc tissues. Objective 9: To determine the expression levels of candidate miRNAs associated with inflammatory processes in human degenerated disc tissues. Objective 10: To compare the expression levels of each candidate miRNA identified in degenerated disc tissues with those found in non-degenerated disc tissues obtained during spinal cord repair surgeries.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
5mo left

Started Apr 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Apr 2025Oct 2026

Study Start

First participant enrolled

April 11, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 31, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 11, 2025

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 12, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 12, 2026

Last Updated

August 11, 2025

Status Verified

August 1, 2025

Enrollment Period

1.5 years

First QC Date

July 31, 2025

Last Update Submit

August 6, 2025

Conditions

Keywords

Disc degenerationmiRNA

Outcome Measures

Primary Outcomes (1)

  • disc degeneration

    degeneration level assessment

    1 year

Secondary Outcomes (1)

  • disc degeneration

    1 year

Study Arms (2)

Degenerated Disc Group (IVDD Group)

EXPERIMENTAL

This group consists of patients diagnosed with lumbar disc herniation (LDH) who are scheduled for lumbar microdiscectomy (LMD) surgery due to intervertebral disc degeneration (IVDD).

Diagnostic Test: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelinesDiagnostic Test: excisedDiagnostic Test: Diagnostic work up

Non-degenerated Disc Control Group

EXPERIMENTAL

This group includes patients undergoing spinal surgery (decompression or fusion) due to vertebral fractures, with no signs of intervertebral disc degeneration. Only patients without degenerative changes on imaging will be included.

Diagnostic Test: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelinesDiagnostic Test: excisedDiagnostic Test: Diagnostic work up

Interventions

During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.

Degenerated Disc Group (IVDD Group)Non-degenerated Disc Control Group
excisedDIAGNOSTIC_TEST

Intervertebral disc tissues that are not degenerated will be collected during surgery and stored in the same manner as in the IVDD group. These samples will be used for comparative analysis of miRNA expression via rt-PCR to serve as the control baseline.

Degenerated Disc Group (IVDD Group)Non-degenerated Disc Control Group
Diagnostic work upDIAGNOSTIC_TEST

During surgery, degenerated intervertebral disc tissues will be collected under sterile conditions and stored at -80°C in cryotubes. miRNA expression profiles will be analyzed using rt-PCR. Candidate miRNAs are selected based on databases such as miRBase, miRTar, and miRDB.

Degenerated Disc Group (IVDD Group)Non-degenerated Disc Control Group

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • ıvdd surgery, fracture suregery

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Çanakkale Onsekiz Mart University

Çanakkale, Çanakkale, 17100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Intervertebral Disc Degeneration

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 31, 2025

First Posted

August 11, 2025

Study Start

April 11, 2025

Primary Completion (Estimated)

October 12, 2026

Study Completion (Estimated)

October 12, 2026

Last Updated

August 11, 2025

Record last verified: 2025-08

Locations